200 related articles for article (PubMed ID: 30279255)
61. Response to ibrutinib in a patient with IgG lymphoplasmacytic lymphoma carrying the MYD88 L265P gene mutation.
Castillo JJ; Ghobrial IM; Treon SP
Leuk Lymphoma; 2016 Nov; 57(11):2699-701. PubMed ID: 26980069
[No Abstract] [Full Text] [Related]
62. Fungal infections in patients treated with ibrutinib: two unusual cases of invasive aspergillosis and cryptococcal meningoencephalitis.
Baron M; Zini JM; Challan Belval T; Vignon M; Denis B; Alanio A; Malphettes M
Leuk Lymphoma; 2017 Dec; 58(12):2981-2982. PubMed ID: 28554246
[No Abstract] [Full Text] [Related]
63. Bing-Neel syndrome: a rare neurological complication of Waldenström macroglobulinaemia.
Alzghoul H; Haider A; Mukhtar F; Khuddus N
BMJ Case Rep; 2024 Jan; 17(1):. PubMed ID: 38182164
[TBL] [Abstract][Full Text] [Related]
64. Radiation therapy and combination of cladribine, cyclophosphamide, and prednisone as treatment of Bing-Neel syndrome: Case report and review of the literature.
Delgado J; Canales MA; Garcia B; Alvarez-Ferreira J; Garcia-Grande A; Hernandez-Navarro F
Am J Hematol; 2002 Feb; 69(2):127-31. PubMed ID: 11835349
[TBL] [Abstract][Full Text] [Related]
65. Ibrutinib for Treating Waldenström's Macroglobulinaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Tappenden P; Carroll C; Stevens J; Simpson E; Thokala P; Wong R; Wright J; Auer R
Pharmacoeconomics; 2019 Jan; 37(1):7-18. PubMed ID: 29951793
[TBL] [Abstract][Full Text] [Related]
66. Isolated central nervous system Aspergillosis infection in a chronic lymphocytic leukemia patient on Ibrutinib: A case report.
Le TH; Kumar V; Gondal K; Barnes M; Siddique H; Buttar B; Kaell A
BMC Infect Dis; 2020 Feb; 20(1):175. PubMed ID: 32093604
[TBL] [Abstract][Full Text] [Related]
67. Rates and Risk of Atrial Arrhythmias in Patients Treated With Ibrutinib Compared With Cytotoxic Chemotherapy.
Fradley MG; Gliksman M; Emole J; Viganego F; Rhea I; Welter-Frost A; Armanious M; Lee DH; Walko C; Shah B; Chavez JC; McLeod H; Pinilla-Ibarz J; Schabath MB
Am J Cardiol; 2019 Aug; 124(4):539-544. PubMed ID: 31208701
[TBL] [Abstract][Full Text] [Related]
68. Nonfluent aphasia in a patient with Waldenstrom's macroglobulinemia.
Donix M; Beuthien-Baumann B; von Kummer R; Gahn G; Thomas F; Holthoff V
J Clin Neurosci; 2007 Jun; 14(6):601-3. PubMed ID: 17376690
[TBL] [Abstract][Full Text] [Related]
69. [Complete response with tirabrutinib for relapsed and refractory Bing-Neel syndrome].
Hagihara M; Ide S; Ohara S; Imai Y; Uchida T; Inoue M
Rinsho Ketsueki; 2022; 63(7):770-775. PubMed ID: 35922946
[TBL] [Abstract][Full Text] [Related]
70. Successful use of Bruton's kinase inhibitor, ibrutinib, to control paraneoplastic pemphigus in a patient with paraneoplastic autoimmune multiorgan syndrome and chronic lymphocytic leukaemia.
Lee A; Sandhu S; Imlay-Gillespie L; Mulligan S; Shumack S
Australas J Dermatol; 2017 Nov; 58(4):e240-e242. PubMed ID: 28295171
[TBL] [Abstract][Full Text] [Related]
71. Ibrutinib suppresses alloantibody responses in a mouse model of allosensitization.
Kim I; Wu G; Chai NN; Klein AS; Jordan S
Transpl Immunol; 2017 Dec; 45():59-64. PubMed ID: 28951258
[TBL] [Abstract][Full Text] [Related]
72. A review of a novel, Bruton's tyrosine kinase inhibitor, ibrutinib.
Lee CS; Rattu MA; Kim SS
J Oncol Pharm Pract; 2016 Feb; 22(1):92-104. PubMed ID: 25425007
[TBL] [Abstract][Full Text] [Related]
73. Impact of ibrutinib dose intensity on patient outcomes in previously treated Waldenström macroglobulinemia.
Castillo JJ; Gustine JN; Meid K; Dubeau TE; Xu L; Yang G; Hunter ZR; Advani R; Palomba L; Treon SP
Haematologica; 2018 Oct; 103(10):e466-e468. PubMed ID: 29773590
[No Abstract] [Full Text] [Related]
74. Waldenstrom macroglobulinemia cells devoid of BTK
Paulus A; Akhtar S; Yousaf H; Manna A; Paulus SM; Bashir Y; Caulfield TR; Kuranz-Blake M; Chitta K; Wang X; Asmann Y; Hudec R; Springer W; Ailawadhi S; Chanan-Khan A
Blood Cancer J; 2017 May; 7(5):e565. PubMed ID: 28548645
[TBL] [Abstract][Full Text] [Related]
75. Targeting CD38 with daratumumab is lethal to Waldenström macroglobulinaemia cells.
Paulus A; Manna A; Akhtar S; Paulus SM; Sharma M; Coignet MV; Jiang L; Roy V; Witzig TE; Ansell SM; Allan J; Furman R; Aulakh S; Manochakian R; Ailawadhi S; Chanan-Khan AA; Sher T
Br J Haematol; 2018 Oct; 183(2):196-211. PubMed ID: 30080238
[TBL] [Abstract][Full Text] [Related]
76. Ibrutinib-induced acute liver failure.
Kahn A; Horsley-Silva JL; Lam-Himlin DM; Reeder CB; Douglas DD; Carey EJ
Leuk Lymphoma; 2018 Feb; 59(2):512-514. PubMed ID: 28693376
[No Abstract] [Full Text] [Related]
77. Imaging spectrum of Bing-Neel syndrome: how can a radiologist recognise this rare neurological complication of Waldenström's macroglobulinemia?
Fitsiori A; Fornecker LM; Simon L; Karentzos A; Galanaud D; Outteryck O; Vermersch P; Pruvo JP; Gerardin E; Lebrun-Frenay C; Lafitte F; Cottier JP; Clerc C; de Seze J; Dietemann JL; Kremer S
Eur Radiol; 2019 Jan; 29(1):102-114. PubMed ID: 29922935
[TBL] [Abstract][Full Text] [Related]
78. Bing-Neel syndrome: Two unexpected cases and a review of the literature.
Van Cauwenberge MG; Depreter B; Dumoulin EN; Emmerechts J; Nollet F; Vanopdenbosch LJ
J Neurol Sci; 2015 Sep; 356(1-2):19-26. PubMed ID: 26159625
[TBL] [Abstract][Full Text] [Related]
79. [A Case of Bing-Neel Syndrome With Repeated Long Spinal Cord Lesions].
Oiwa K; Shirai S; Abe M; Ohigashi H; Iwata I; Otsuka T; Yabe I
Brain Nerve; 2023 Jan; 75(1):69-75. PubMed ID: 36574974
[TBL] [Abstract][Full Text] [Related]
80. Working Toward a Genomic Prognostic Classification of Waldenström Macroglobulinemia: C-X-C Chemokine Receptor Type 4 Mutation and Beyond.
Magierowicz M; Tomowiak C; Leleu X; Poulain S
Hematol Oncol Clin North Am; 2018 Oct; 32(5):753-763. PubMed ID: 30190015
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
